Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer

被引：57
|
作者：
Boumber, Yanis [1 ,2 ,3 ]
机构：
[1] Fox Chase Canc Ctr, Program Mol Therapeut, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Kazan Fed Univ, Insititute Fundamental Med & Biol, Kazan, Russia
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷 / 08期
基金：
俄罗斯基础研究基金会;
关键词：
NIVOLUMAB PLUS IPILIMUMAB; TOPOTECAN; BLOCKADE;
D O I：
10.21037/jtd.2018.07.120
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：4689 / 4693
页数：5
相关论文
共 50 条
  • [21] Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer
    Barroso-Sousa, Romualdo
    Jain, Esha
    Kim, Dewey
    Partridge, Ann H.
    Cohen, Ofir
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Notch 1/2/3 mutation as a potential biomarker for immunotherapy in smokers with non-small cell lung cancer via increasing tumor mutational burden
    Hong, Xiaohua
    Shen, Aijun
    Xu, Yu
    Li, Chengcheng
    Wang, Guoqiang
    Liu, Li
    Qi, Chuang
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Comparison of platforms for determining tumor mutational burden (TMB) from blood samples in patients with non-small cell lung cancer (NSCLC)
    Baden, J.
    Chang, H.
    Greenawalt, D. M.
    Kirov, S.
    Pant, S.
    Seminara, A.
    Srinivasan, S.
    Green, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 28 - 28
  • [24] The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non-small cell lung cancer
    Li, Yalun
    Ji, Liyan
    Zhang, Yingqian
    Zhang, Jiexin
    Reuben, Alexandre
    Zeng, Hao
    Huang, Qin
    Wei, Qi
    Tan, Sihan
    Xia, Xuefeng
    Li, Weimin
    Zhang, Jianjun
    Tian, Panwen
    MEDCOMM, 2024, 5 (06):
  • [25] Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology
    Ansari, Afzal
    Ray, Suman Kumar
    Sharma, Mukul
    Rawal, Rakesh
    Singh, Pushpendra
    CURRENT MOLECULAR MEDICINE, 2024, 24 (12) : 1461 - 1469
  • [26] The clinical utility of tumor mutational burden in non-small cell lung cancer
    Greillier, Laurent
    Tomasini, Pascale
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 639 - 646
  • [27] Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in Non-Small-Cell Lung Cancer
    Brawley, Otis W.
    Luhn, Patricia
    Reese-White, Deonna
    Ogbu, Uzor C.
    Madhavan, Sriraman
    Wilson, Gerren
    Cox, Meghan
    Ewing, Altovise
    Hammer, Christian
    Richie, Nicole
    JCO GLOBAL ONCOLOGY, 2021, 7 : 1537 - 1546
  • [28] Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
    Lee, Mark
    Samstein, Robert M.
    Valero, Cristina
    Chan, Timothy A.
    Morris, Luc G. T.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (01) : 112 - 115
  • [29] Comparison of platforms for determining tumour mutational burden (TMB) in patients with non-small cell lung cancer (NSCLC)
    Baden, J.
    Zhao, C.
    Pratt, J.
    Kirov, S.
    Pant, S.
    Seminara, A.
    Green, G.
    Bilke, S.
    Deras, I.
    Fabrizio, D. A.
    Pawlowski, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [30] Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence
    Passaro, Antonio
    Stenzinger, Albrecht
    Peters, Solange
    CANCER CELL, 2020, 38 (05) : 624 - 625
12345